• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Singulex

edit

Singulex, Inc., a biotechnology company, develops and commercializes direct molecular detection technology solutions. Its solutions enable life science researchers and clinicians to understand and manage disease. The company develops biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers. It is conducting pilot studies to validate Erenna BioAssay System, a digital molecule detection platform, which detects and quantifies molecule biomarkers in clinical samples. The company also offers various custom assay services, such as pilot study services, assay prototyping, assay characterization, and assay validation. The company was formerly known as BioProfile Corporation and changed its name to Singulex, Inc in September 2003. Singulex is based in Hayward, California

Recent Milestones

edit

• 
  Singulex received $12.2M in Series G funding. (6/7/13)
  Posted 6/10/13 at 2:10am via sec.gov
• 
  Singulex received $19M in Series E funding. (1/12/09)
  Posted 6/13/09 at 8:21am via bio-medicine.org
• 
  Singulex received $19M in Series D funding. (6/7/07)
  Posted 6/19/09 at 11:14am via venturebeat.com
• 
  Singulex received $9.35M in Series C funding. (7/17/06)
  Posted 4/23/10 at 7:31pm
• 
  Singulex added Philippe J. Goix as President and Chief Executive Officer.
  Posted 1/4/13 at 5:41am
• 
  Singulex added Michael Bell as Chief Financial Officer.
  Posted 1/4/13 at 5:41am

Videos

Screenshots

edit

Above: Singulex Screenshot -- #1
Uploaded: 6/13/09

Sources

1. EDGAR [edit]
2. Biomarker-diagnostics developer Singulex validates $19M (venturebeat.com) [edit]
3. Singulex Closes $19 Million Financing Round (bio-medicine.org) [edit]
4. SEC (sec.gov) [edit]